Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $62.25

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $62.25.

A number of analysts have recently weighed in on CLDX shares. Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price target on the stock. Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Finally, Wolfe Research downgraded Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Friday, September 27th.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX traded down $1.01 during trading hours on Tuesday, reaching $26.22. The company's stock had a trading volume of 353,848 shares, compared to its average volume of 883,246. Celldex Therapeutics has a 1 year low of $22.93 and a 1 year high of $53.18. The firm has a 50-day simple moving average of $28.26 and a 200-day simple moving average of $34.21. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -10.20 and a beta of 1.57.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Celldex Therapeutics by 5.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company's stock worth $1,449,000 after purchasing an additional 2,070 shares during the period. Geode Capital Management LLC lifted its position in Celldex Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock worth $52,372,000 after buying an additional 6,557 shares during the last quarter. Barclays PLC boosted its stake in Celldex Therapeutics by 140.7% during the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after buying an additional 76,207 shares during the period. Y Intercept Hong Kong Ltd increased its position in Celldex Therapeutics by 11.5% during the third quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company's stock valued at $1,038,000 after acquiring an additional 3,146 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Celldex Therapeutics in the third quarter valued at $1,561,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.